Multiple sclerosis classification: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 19: Line 19:
[[PRMS]] is defined by progression of [[disease]] from the beginning with acute attack episodes.<ref name=":0" />
[[PRMS]] is defined by progression of [[disease]] from the beginning with acute attack episodes.<ref name=":0" />


These subtypes were defined In 1996 by the US [[National Multiple Sclerosis Society]] (NMSS).<ref name=":0" />
These subtypes were defined In 1996 by the US [[National Multiple Sclerosis Society]] ([[NMSS]]).<ref name=":0" />


In recent studies a new subtype recognized and named: '''clinically isolated syndrome (CIS)'''. It is when the clinical presentation of a disease is suggestive of myelin sheet inflammation but cannot fulfill the diagnostic criteria of MS.<ref name="pmid24871874">{{cite journal |vauthors=Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH |title=Defining the clinical course of multiple sclerosis: the 2013 revisions |journal=Neurology |volume=83 |issue=3 |pages=278–86 |year=2014 |pmid=24871874 |pmc=4117366 |doi=10.1212/WNL.0000000000000560 |url=}}</ref>  
In recent studies a new subtype recognized and named: '''[[clinically isolated syndrome]] ([[CIS]])'''. It is when the [[clinical]] presentation of a [[disease]] is suggestive of [[myelin sheath]] [[inflammation]] but cannot fulfill the [[diagnostic criteria]] of [[MS]].<ref name="pmid24871874">{{cite journal |vauthors=Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH |title=Defining the clinical course of multiple sclerosis: the 2013 revisions |journal=Neurology |volume=83 |issue=3 |pages=278–86 |year=2014 |pmid=24871874 |pmc=4117366 |doi=10.1212/WNL.0000000000000560 |url=}}</ref>  


==References==
==References==

Revision as of 10:43, 21 January 2018

Multiple sclerosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple sclerosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography or Ultrasound

CT Scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Alternative Therapies

Primary Prevention

Secondary Prevention

Tertiary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Multiple sclerosis classification On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple sclerosis classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple sclerosis classification

CDC on Multiple sclerosis classification

Multiple sclerosis classification in the news

Blogs on Multiple sclerosis classification

Directions to Hospitals Treating Multiple sclerosis

Risk calculators and risk factors for Multiple sclerosis classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Classification

Multiple sclerosis may be classified according to clinical course into four groups:[1]

Relapsing-remitting:

RRMS is defined by acute attacks of neurological dysfunction followed by full or partial recovery. Patient clinical symptoms are stable between the attacks.[1]

Secondary progressive:

Patient with long term RRMS can switch to SPMS, when the neurological symptoms progressively worsen between the attacks.[1]

Primary progressive:

PPMS is defined by continuously worsening of neurological dysfunction with no distinct attacks and remissions.[1]

Progressive relapsing:

PRMS is defined by progression of disease from the beginning with acute attack episodes.[1]

These subtypes were defined In 1996 by the US National Multiple Sclerosis Society (NMSS).[1]

In recent studies a new subtype recognized and named: clinically isolated syndrome (CIS). It is when the clinical presentation of a disease is suggestive of myelin sheath inflammation but cannot fulfill the diagnostic criteria of MS.[2]

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 Lublin FD; Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996 Apr;46(4):907-11. PMID 8780061
  2. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH (2014). "Defining the clinical course of multiple sclerosis: the 2013 revisions". Neurology. 83 (3): 278–86. doi:10.1212/WNL.0000000000000560. PMC 4117366. PMID 24871874.

Template:WH Template:WS